Dysregulated lipid metabolism blunts the sensitivity of cancer cells to EZH2 inhibitor

BACKGROUND: Sensitivity has been a key issue for Enhancer of zeste homolog 2 (EZH2) inhibitors in cancer therapy. The EZH2 inhibitor EPZ-6438 was first approved by the US Food and Drug Administration (FDA) in 2020. However, its inadequate anti-cancer activity in solid tumors limits its clinical appl...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Tengrui, Guo, Zhengyang, Huo, Xiao, Gong, Yueqing, Li, Chen, Huang, Jiaqi, Wang, Yan, Feng, Hao, Ma, Xiaojuan, Jiang, Changtao, Yin, Qianqian, Xue, Lixiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850333/
https://www.ncbi.nlm.nih.gov/pubmed/35158113
http://dx.doi.org/10.1016/j.ebiom.2022.103872

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850333/
https://www.ncbi.nlm.nih.gov/pubmed/35158113
http://dx.doi.org/10.1016/j.ebiom.2022.103872

Ejemplares similares